Literature DB >> 18348467

Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing.

P Venkatesh1, T Harisudhan, Hira Choudhury, Ramesh Mullangi, Nuggehally R Srinivas.   

Abstract

A uranyl nitrate-induced model of acute renal failure (UN-ARF) for various time periods was used to study its effect on the disposition of several drugs like chlorzoxazone, clarithromycin, vancomycin, methotrexate etc. An attempt to optimize the duration of UN dosing with respect to the pharmacokinetics of etoposide in rats was carried out after intravenous (i.v.) dosing of UN at 5 mg/kg for 1, 3, 5 and 7 days. Irrespective of the duration of UN dosing apart from day 1, ARF was observed, with significantly increased serum levels of creatinine (0.36 +/- 0.11 for controls vs 2.44 +/- 0.72 [day 7] for UN-ARF rats) and urea (33.71 +/- 9.46 for controls vs. 169.2 +/- 9.71 [day 5] for UN-ARF rats) in all the UN-treated groups. It has been reported that ARF may alter the pharmacokinetics (PK) and the exposure of renally eliminated drugs. Further, as exposure to etoposide has a correlation with toxicity, the need to investigate the possible alterations in etoposide pharmacokinetics in the UN-ARF model could be of significance. The PK of etoposide was therefore investigated in control and UN-ARF rats after a single i.v. dose of 25 mg/kg. The concentrations of etoposide in the plasma were determined by high- performance liquid chromatography (HPLC) method with fluorescence detector set at excitation and emission wavelengths of 380 and 520 nm respectively. The metabolic stability of etoposide was investigated in rat liver microsomes prepared from control and UN-ARF treated rats. The PK results showed increased plasma levels and systemic exposure to etoposide (19.97 +/- 2.12 for control vs 29.03 +/- 2.32, 34.45 +/- 3.37, 34.19 +/- 2.98 for 3, 5 and 7day UN-treated groups respectively), i.e. for all UN-ARF groups except for 1-day UN-ARF rats (20.06 +/- 1.53). Incubation with liver microsomes from UN-ARF rats treated for up to 5 days and control rats showed no significant difference in etoposide metabolism suggesting that the CYP3A4 isoenzyme responsible for the metabolism of etoposide was not considerably expressed thereby leading to the conclusion that 3 days UN dosing was sufficient to induce ARF in rats, and that the dose of etoposide required needs to be monitored due to altered PK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18348467     DOI: 10.1007/BF03191003

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

1.  Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate.

Authors:  Ae K Lee; Joo H Lee; Jong W Kwon; Won B Kim; Sang G Kim; So H Kim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2004-09       Impact factor: 1.627

2.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes.

Authors:  T Kawashiro; K Yamashita; X J Zhao; E Koyama; M Tani; K Chiba; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

3.  Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.

Authors:  J M Park; C H Moon; M G Lee
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1996-09

4.  Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): the role of urea in CYP2E1 induction by acute renal failure.

Authors:  Hye Chin Chung; So Hee Kim; Myung Gull Lee; Sang Geon Kim
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

5.  Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats.

Authors:  Young Jin Moon; Ae Kyung Lee; Hye Chin Chung; Eun Jung Kim; So Hee Kim; Duk Chul Lee; Inchul Lee; Sang Geon Kim; Myung Gull Lee
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

6.  Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation.

Authors:  Su Yeon Yu; Hye Chin Chung; Eun Jung Kim; So Hee Kim; Inchull Lee; Sang Geon Kim; Myung Gull Lee
Journal:  J Pharm Pharmacol       Date:  2002-12       Impact factor: 3.765

Review 7.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

8.  Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.

Authors:  Y H Lee; M H Lee; C K Shim
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

9.  Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat.

Authors:  R J Fruncillo; B N Swanson; R Bernhard; C Marchion; R K Ferguson
Journal:  J Pharm Sci       Date:  1986-02       Impact factor: 3.534

10.  Effect of experimental renal failure on the pharmacokinetics of losartan in rats.

Authors:  Takashi Yoshitani; Hitoshi Yagi; Nobuo Inotsume; Masato Yasuhara
Journal:  Biol Pharm Bull       Date:  2002-08       Impact factor: 2.233

View more
  2 in total

Review 1.  Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury.

Authors:  A Mary Vilay; Mariann D Churchwell; Bruce A Mueller
Journal:  Crit Care       Date:  2008-11-12       Impact factor: 9.097

Review 2.  Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism.

Authors:  John Dixon; Katie Lane; Iain Macphee; Barbara Philips
Journal:  Int J Mol Sci       Date:  2014-02-13       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.